ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0JJM Bioporto A/s

3.20
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioporto A/s LSE:0JJM London Ordinary Share DK0011048619 BIOPORTO ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 28.97M -75.92M -0.2268 -14.11 1.07B

BioPorto and Roche Diagnostics sign a distribution agreement for NGAL

09/02/2018 7:22am

GlobeNewswire Inc.


Bioporto A/s (LSE:0JJM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Bioporto A/s Charts.
BioPorto and Roche Diagnostics sign a distribution agreement for NGAL

BioPorto A/S (“BioPorto”) has entered into a global distribution agreement with Roche, under which BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c 501/c 502 analysers.

The agreement has significant strategic importance to ensure the expanded availability of NGAL tests, as well as enhancing the awareness of NGAL as a diagnostic marker for acute kidney injury. BioPorto expects the agreement to generate revenue starting in 2019.

Under the terms of the agreement, Roche will have worldwide exclusive distribution rights for the NGAL test adapted for use on Roche’s cobas c 501/c 502 systems. 

The NGAL Test™ is CE marked and BioPorto is currently conducting clinical studies to generate data for FDA approval, which is expected later this year. 

Peter Mørch Eriksen, CEO of BioPorto, said "I am very happy to enter into a collaboration with Roche, who as a dominant player in the diagnostic space will ensure a broad global distribution of our NGAL test to address a critical need in patient care today.” 

For further information, please contact:Peter Mørch Eriksen, CEOGry Husby Larsen, General CounselTelephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGALEvery year about 13 million people are affected by acute kidney injury worldwide, of which about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.

About BioPortoBioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock exchange.

http://prlibrary-eu.nasdaq.com/Resource/Download/5530efef-9b7e-4a45-ae52-199ef29dce7a

1 Year Bioporto A/s Chart

1 Year Bioporto A/s Chart

1 Month Bioporto A/s Chart

1 Month Bioporto A/s Chart

Your Recent History

Delayed Upgrade Clock